Franklin FTSE South Korea ETF vs Moderna, Inc. — how do they compare? Franklin FTSE South Korea ETF trades at $58.12 (market cap $1.88B), while Moderna, Inc. trades at $196.76 (market cap $78.44B). The key difference: Moderna, Inc. is far larger — about 41.7× Franklin FTSE South Korea ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Franklin FTSE South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Moderna, Inc. for 59 Days on average.
| FLKR | MRNA | |
|---|---|---|
Market Cap | $1.88B | $78.44B |
Volume | 709,775 | 14,597,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $203.46 |
52-Week Low | $27.09 | $22.36 |
Typical Hold Time | 15 Days | 59 Days |
Enterprise Value | — | $74.59B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →